Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) Net Margin (2016 - 2025)

Ironwood Pharmaceuticals' Net Margin history spans 16 years, with the latest figure at 174.85% for Q4 2025.

  • For Q4 2025, Net Margin fell 17734.0% year-over-year to 174.85%; the TTM value through Dec 2025 reached 18.94%, down 1921.0%, while the annual FY2025 figure was 38.88%, 3863.0% up from the prior year.
  • Net Margin for Q4 2025 was 174.85% at Ironwood Pharmaceuticals, down from 32.8% in the prior quarter.
  • Across five years, Net Margin topped out at 376.14% in Q2 2021 and bottomed at 1014.62% in Q2 2023.
  • The 5-year median for Net Margin is 30.22% (2025), against an average of 30.68%.
  • The largest annual shift saw Net Margin plummeted -105276bps in 2023 before it skyrocketed 101371bps in 2024.
  • A 5-year view of Net Margin shows it stood at 35.33% in 2021, then skyrocketed by 203bps to 106.95% in 2022, then plummeted by -282bps to 194.18% in 2023, then surged by 101bps to 2.49% in 2024, then tumbled by -7118bps to 174.85% in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Net Margin are 174.85% (Q4 2025), 32.8% (Q3 2025), and 27.64% (Q2 2025).